Risk profile tool provides clearer insight on hospitalized COVID-19 patients who benefit most from baricitinib treatment
A post-hoc analysis of ACTT-2 (Adaptive COVID-19 Treatment Trial-2) found that the use of a risk profile may more precisely characterize high-risk patients who may benefit from the use of baricitinib. The analysis is published in Annals of Internal Medicine.
Facebook Comments
https://www.sarkaridoctor.com/wp-content/uploads/2022/01/logo@2xx.png00aajahttps://www.sarkaridoctor.com/wp-content/uploads/2022/01/logo@2xx.pngaaja2024-02-27 12:04:172024-02-27 12:04:17Risk profile tool provides clearer insight on hospitalized COVID-19 patients who benefit most from baricitinib treatment
Learning and memory problems in Down syndrome linked to alterations in genome’s...